https://scholars.lib.ntu.edu.tw/handle/123456789/535285
標題: | Pharmacotherapy of post-transplant viral infections | 作者: | HSIN-YUN SUN Singh N. |
公開日期: | 2008 | 卷: | 9 | 期: | 14 | 起(迄)頁: | 2409-2421 | 來源出版物: | Expert Opinion on Pharmacotherapy | 摘要: | Background: Management of a number of significant viral pathogens in transplant recipients remains challenging. Objectives: To define an optimal antiviral approach to the management of cytomegalovirus (CMV), human herpes virus-6 (HHV-6), Epstein-Barr (EBV)-associated post-transplant lymphoproliferative disorder (PTLD), and polyoma virus-associated nephropathy in transplant recipients. Methods: Clinical trials and existing data regarding use of antiviral agents for these viruses were reviewed to develop evidence-based recommendations for their management. Conclusions: Weighing the current evidence regarding the use of valganciclovir as pre-emptive therapy or prophylaxis, the former approach offers a greater benefit for the overall prevention of CMV disease. Limited data show that prophylaxis with antiviral agents is associated with a reduction in the risk of EBV-associated PTLD. Treatment options for HHV-6 and polyoma virus-associated nephropathy are still limited. ? 2008 Informa UK Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-54349113570&doi=10.1517%2f14656566.9.14.2409&partnerID=40&md5=4e8982e3d2c691313097ee081a444433 https://scholars.lib.ntu.edu.tw/handle/123456789/535285 |
ISSN: | 1465-6566 | DOI: | 10.1517/14656566.9.14.2409 | SDG/關鍵字: | aciclovir; antivirus agent; benzimidavir; cidofovir; cyclophosphamide; Cytomegalovirus antibody; daunorubicin; doxorubicin; foscarnet; ganciclovir; gatifloxacin; immunoglobulin; leflunomide; lymphocyte antibody; mycophenolic acid 2 morpholinoethyl ester; placebo; prednisolone; quinoline derived antiinfective agent; rituximab; tacrolimus; valaciclovir; valganciclovir; vincristine; adjuvant therapy; antiviral activity; area under the curve; clinical trial; combination chemotherapy; cost effectiveness analysis; Cytomegalovirus; cytomegalovirus infection; drug dose increase; drug efficacy; drug fatality; drug half life; drug potency; drug selectivity; drug substitution; drug tolerability; drug treatment failure; drug withdrawal; Epstein Barr virus; graft infection; heart transplantation; Herpes virus infection; human; Human herpesvirus 6; immunosuppressive treatment; infection prevention; kidney disease; kidney transplantation; liver transplantation; low drug dose; lymphoproliferative disease; maximum plasma concentration; meningoencephalitis; monotherapy; multidrug resistance; nausea and vomiting; nephrotoxicity; neutropenia; nonhuman; pneumonia; Polyoma virus; postoperative infection; review; risk reduction; surgical patient; taste disorder; thrombocytopenia; time to maximum plasma concentration; unspecified side effect; uveitis; viremia; virus infection; Antiviral Agents; Herpesviridae Infections; Humans; Kidney Diseases; Lymphoproliferative Disorders; Postoperative Complications; Transplantation |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。